Outcomes after Implantation of a Latest Generation Biological Valve with a New Anticalcification Treatment

Background: This latest generation aortic valve is a pericardial bio-prosthesis with a new anticalcification treatment that shows promising in vitro results in terms of reduced calcification. Only limited follow up data is available due to the novelty of this valve.

Methods: A total of 110 patients underwent AVR using a novel bioprosthetic valve December 2018 and January 2022. Procedural, early (<30 days) and late (>30 days) outcomes were collected. Echocardiographic evaluation of hemodynamic performance was performed after 1 year and 3 years. The median follow up time was 3.8 years.

Results: The mean age was 68.3 ± 7.9 years, and the mean logistic Euroscore II 2.1 ± 1.3%. Early all-cause mortality was 1.8% (n = 2) A stroke rate of 0.9% (n = 1) occurred. Major paravalvular leaks did not occur. New pacemaker implantation rate was 4.5% (n = 5). Five-year actuarial freedom from all-cause mortality, structural valve deterioration, and all-cause reintervention were 92.1%, 100%, and 97.6%, respectively. One case of endocarditis was in seen in the follow up period. At 3 years, the mean effective orifice area was 1.7 ± 0.3 cm² with a mean gradient of 10.4 ± 3.8 mmHg. 98.1% of patients had none/trivial paravalvular leakage and 97.7% had non/trivial transvalvular regurgitation, respectively.

Conclusion: This latest generation bioprosthesis offers excellent safety and hemodynamic performance with minimal regurgitation and no evidence of structural valve deterioration.

 

Scroll to top

Die Autoren geben an, dass kein Interessenkonflikt besteht.

Publikationsverlauf

Artikel online veröffentlicht:
13. Februar 2024